It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
Subscribe To Our Newsletter & Stay Updated
